---
title: "BlackRock Health Sciences Term Trust files Form 3 for Chief Compliance Officer Charles Park"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295028241.md"
description: "BlackRock Health Sciences Term Trust filed Form 3 with the SEC, appointing Charles Park as Chief Compliance Officer effective August 1, 2026. The filing was published via EDGAR on August 5, 2026."
datetime: "2026-08-05T23:12:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295028241.md)
  - [en](https://longbridge.com/en/news/295028241.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295028241.md)
generator: "portal-rs"
---

# BlackRock Health Sciences Term Trust files Form 3 for Chief Compliance Officer Charles Park

-   BlackRock Health Sciences Term Trust filed a Form 3 naming Charles Park as chief compliance officer, effective Aug. 1, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Blackrock Health Sciences Term Trust published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-335772), on August 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [BMEZ.US](https://longbridge.com/en/quote/BMEZ.US.md)

## Related News & Research

- [Inter Parfums announces availability of 2026 half-year report](https://longbridge.com/en/news/298413126.md)
- [Tractor Supply declares R$ 0.05 per-unit dividend for Q3 2026](https://longbridge.com/en/news/298615733.md)
- [HF Sinclair announces Q3 2026 dividend of R$ 1.81 per unit](https://longbridge.com/en/news/298317474.md)
- [BioLineRx outlines Phase 1/2a GLIX1 trial in recurrent high-grade glioma at EANO 2026](https://longbridge.com/en/news/298582374.md)
- [Biovica publishes Q1 2026/27 quarterly report release](https://longbridge.com/en/news/298482629.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**